title: Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters.
abstract: Serotonin (5-hydroxytryptamine, 5-HT) has long been implicated in regulation of mood. Medications that block the neuronal 5-HT transporter (SERT) are used as major pharmacological treatment for mood disorders. Conversely, stimuli that enhance SERT activity might be predicted to diminish synaptic 5-HT availability and increase the risk for 5-HT-related CNS disorders. We have shown that the inflammatory cytokines enhance brain SERT activity in cultured serotonergic cells and nerve terminal preparations in vitro. In this study, we establish that intraperitoneal injection of the cytokine-inducer lipopolysaccharide (LPS) stimulates brain SERT activity, acting at doses below those required to induce overt motor suppression. SERT stimulation by LPS is paralleled by increased immobility in both the tail suspension test (TST) and the forced swim test (FST); antidepressant-sensitive alterations are thought to model aspects of behavioral despair. Both the stimulation of SERT activity and induced immobility are absent when LPS is administered to interleukin-1 receptor (IL-1R)-deficient mice and in the presence of SB203580, an inhibitor of IL-1R-stimulated p38 MAPK. Moreover, the ability of LPS to enhance immobility in TST is lost in SERT knockout mice. These findings reveal an ability of peripheral inflammatory stimuli to enhance brain SERT activity through IL-1R and p38 MAPK pathways in vivo and identify a requirement for SERT expression in immune-system-modulated despair behaviors. Our studies identify IL-1R- and p38 MAPK-dependent regulation of SERT as one of the mechanisms by which environmentally driven immune system activation can trigger despair-like behavior in an animal model, encouraging future analysis of the pathway for risk factors in neuropsychiatric disorders.
authors.affiliation: Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
authors.forename: Chong-Bin
authors.initials: CB
authors.lastname: Zhu
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Lindler
authors.forename: Anthony W
authors.initials: AW
authors.lastname: Owens
authors.forename: Lynette C
authors.initials: LC
authors.lastname: Daws
authors.forename: Randy D
authors.initials: RD
authors.lastname: Blakely
authors.forename: William A
authors.initials: WA
authors.lastname: Hewlett
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003863:Depression / Q000139:chemically induced* / Q000517:prevention & control; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011725:Pyridines / Q000494:pharmacology; D017472:Receptors, Interleukin-1 / Q000235:genetics / Q000378:metabolism*; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism*; D013574:Synaptosomes / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*
chemical_list: D004791:Enzyme Inhibitors; D007093:Imidazoles; D008070:Lipopolysaccharides; D011725:Pyridines; D017472:Receptors, Interleukin-1; D050486:Serotonin Plasma Membrane Transport Proteins; C493231:Slc6a4 protein, mouse; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580
references.citation: Psychopharmacology (Berl). 2001 Feb;154(1):50-60
references.pmid: 11292006
references.citation: Brain Res. 1996 Mar 4;711(1-2):163-74
references.pmid: 8680860
references.citation: Mol Psychiatry. 2003 Nov;8(11):933-6
references.pmid: 14593431
references.citation: Adv Exp Med Biol. 1999;461:283-316
references.pmid: 10442179
references.citation: Eur J Neurosci. 2008 Dec;28(12):2499-510
references.pmid: 19087175
references.citation: Nat Rev Neurosci. 2008 Jan;9(1):46-56
references.pmid: 18073775
references.citation: Biochem Biophys Res Commun. 1995 Nov 13;216(2):560-7
references.pmid: 7488148
references.citation: Adv Exp Med Biol. 1999;461:25-46
references.pmid: 10442165
references.citation: Mol Psychiatry. 2009 May;14(5):511-22
references.pmid: 18195714
references.citation: Brain Behav Immun. 2006 Nov;20(6):569-77
references.pmid: 16554144
references.citation: Brain Behav Immun. 2003 Feb;17 Suppl 1:S119-24
references.pmid: 12615197
references.citation: Gynecol Endocrinol. 1996 Jun;10(3):149-54
references.pmid: 8862488
references.citation: Curr Psychiatry Rep. 2006 Dec;8(6):452-7
references.pmid: 17094925
references.citation: Neuroendocrinology. 1992 Dec;56(6):935-8
references.pmid: 1369606
references.citation: Mol Psychiatry. 2008 Jul;13(7):717-28
references.pmid: 17700577
references.citation: Physiology (Bethesda). 2005 Aug;20:225-31
references.pmid: 16024510
references.citation: Pharmacol Biochem Behav. 1993 Dec;46(4):787-91
references.pmid: 8309956
references.citation: Psychoneuroendocrinology. 2003 Jan;28(1):19-34
references.pmid: 12445834
references.citation: Brain Res. 1995 Dec 24;705(1-2):302-6
references.pmid: 8821761
references.citation: Acta Psychiatr Scand. 1988 Aug;78(2):176-81
references.pmid: 3223316
references.citation: Acta Psychiatr Scand. 2001 Mar;103(3):226-8
references.pmid: 11240580
references.citation: CNS Neurol Disord Drug Targets. 2006 Oct;5(5):547-60
references.pmid: 17073657
references.citation: J Neuroinflammation. 2008 Mar 18;5:10
references.pmid: 18348728
references.citation: Neurosci Lett. 2009 May 29;456(1):39-43
references.pmid: 19429130
references.citation: Neurochem Int. 1998 Sep;33(3):251-4
references.pmid: 9759920
references.citation: Psychosom Med. 2009 Feb;71(2):171-86
references.pmid: 19188531
references.citation: Brain Res. 1995 Oct 16;695(2):279-82
references.pmid: 8556346
references.citation: Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):751-6
references.pmid: 18178625
references.citation: Neuropsychobiology. 1996;33(4):202-9
references.pmid: 8840344
references.citation: J Neuroimmunol. 2005 Jun;163(1-2):53-72
references.pmid: 15885308
references.citation: Neuropsychopharmacology. 2001 May;24(5):531-44
references.pmid: 11282253
references.citation: Nat Rev Neurosci. 2003 Dec;4(12):1002-12
references.pmid: 14618156
references.citation: J Neurosci Res. 1995 Feb 15;40(3):407-13
references.pmid: 7745636
references.citation: J Pharmacol Exp Ther. 2001 Nov;299(2):666-77
references.pmid: 11602680
references.citation: Curr Opin Investig Drugs. 2009 Jul;10(7):664-71
references.pmid: 19579172
references.citation: Science. 2003 Jul 18;301(5631):386-9
references.pmid: 12869766
references.citation: Am J Geriatr Psychiatry. 2010 Feb;18(2):172-6
references.pmid: 20104073
references.citation: Clin Neurosci Res. 2006 Aug;6(1-2):52-68
references.pmid: 18079991
references.citation: Pharmacol Biochem Behav. 2007 Apr;86(4):651-9
references.pmid: 17360031
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):85-102
references.pmid: 12551730
references.citation: Neurosci Lett. 2009 Feb 13;451(1):79-82
references.pmid: 19103261
references.citation: Infect Immun. 1990 Nov;58(11):3743-50
references.pmid: 2228245
references.citation: Neurosci Biobehav Rev. 2005;29(4-5):571-625
references.pmid: 15890404
references.citation: Alcohol Clin Exp Res. 2009 Aug;33(8):1329-35
references.pmid: 19426172
references.citation: J Psychiatry Neurosci. 2009 Jan;34(1):4-20
references.pmid: 19125209
references.citation: J Affect Disord. 2001 Jan;62(1-2):57-76
references.pmid: 11172874
references.citation: Trends Immunol. 2006 Jan;27(1):24-31
references.pmid: 16316783
references.citation: Philos Trans R Soc Lond B Biol Sci. 2009 Jan 27;364(1514):163-73
references.pmid: 18957375
references.citation: Life Sci. 2001 Jan 12;68(8):873-80
references.pmid: 11213357
references.citation: Biol Psychiatry. 2010 Mar 1;67(5):446-57
references.pmid: 20015486
references.citation: Psychopharmacology (Berl). 2003 Dec;170(4):429-33
references.pmid: 12955291
references.citation: J Psychopharmacol. 2007 Jul;21(5):538-44
references.pmid: 17446201
references.citation: Neuropsychopharmacology. 2006 Oct;31(10):2121-31
references.pmid: 16452991
references.citation: Ann N Y Acad Sci. 2000;917:478-87
references.pmid: 11268375
references.citation: J Neurosci. 2005 Jan 5;25(1):29-41
references.pmid: 15634764
references.citation: Exp Gerontol. 2007 Jul;42(7):693-701
references.pmid: 17350781
references.citation: Int J Neuropsychopharmacol. 2009 Jul;12(6):737-47
references.pmid: 19154632
references.citation: J Biol Chem. 2005 Apr 22;280(16):15649-58
references.pmid: 15728187
references.citation: Physiol Behav. 2009 Aug 4;98(1-2):139-46
references.pmid: 19414023
references.citation: Ann N Y Acad Sci. 2006 Nov;1088:230-7
references.pmid: 17192569
references.citation: Neuropsychobiology. 1999 Nov;40(4):171-6
references.pmid: 10559698
references.citation: Mol Psychiatry. 2007 Nov;12(11):988-1000
references.pmid: 17457312
references.citation: Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18976-81
references.pmid: 19033200
references.citation: Eur J Neurosci. 2005 Dec;22(11):2817-26
references.pmid: 16324116
references.citation: J Neurosci Res. 2003 Mar 1;71(5):701-9
references.pmid: 12584728
references.citation: Pharmacol Biochem Behav. 2005 Jul;81(3):688-93
references.pmid: 15982728
references.citation: J Neuroimmunol. 2000 Apr 3;104(1):31-6
references.pmid: 10683512